Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSTATRE: Risperidone LAI vs Quetiapine in Schizophrenia
NCT00216476Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2004
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of risperidone in schizophrenia, schizoaffective disorder, sponsored by Janssen Pharmaceutical. Started Oct 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00216476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216476.